Total Funding
27
43
Total FundingGrant raised
Growth Score
-4 pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
218568
Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists.
- Dennis McNamara: Chief Executive Officer and Co-Founder
- Ray Dingledine: Co-Founder & Chair of Board of Directors
About the Company
Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists. The drugs Pyrefin is testing have myriad potential uses, including treatment for epileptic seizures.
Rodent trials have shown efficacy in treatment for seizure-induced brain injury, endometriosis, and osteoarthritis without behavioral or organ
toxicity after 30 days.
Phase 1A of GRA’s venture development support focused Pyrefin’s team on prioritizing the clinical use of its treatment.
